Over-expression by degradation rescue of RTKs via cancer-secreted autocrine growth factors:

RTK UPS UbE3L degron gf pDegron paDegron piDegron

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 16 08 2023
accepted: 06 09 2023
medline: 12 10 2023
pubmed: 12 10 2023
entrez: 12 10 2023
Statut: epublish

Résumé

Recently published work provide the first known evidence of a malignancy-associated regulatory mechanism, functionally connecting a phospho-regulated degron domain embedded in a receptor tyrosine kinase (RTK), with its ectopic expression in cancer, conditional to a specific autocrine growth factor signal. Mechanistically, the growth factor-triggered phosphorylation inhibits the degron domain present in the regulated RTK, blocking access to a specific degradation complex. This ultimately rescues the RTK from rapid ubiquitin-proteasome-system-mediated degradation and, most importantly, causes its cellular overexpression. This mechanism, which has been here assigned the new functional name "

Identifiants

pubmed: 37823054
doi: 10.3389/fonc.2023.1278402
pmc: PMC10562641
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1278402

Informations de copyright

Copyright © 2023 Scalia and Williams.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int J Mol Sci. 2023 Apr 17;24(8):
pubmed: 37108544
Cells. 2023 Jun 21;12(13):
pubmed: 37443713
Mol Endocrinol. 2011 Aug;25(8):1456-68
pubmed: 21680660
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):358-366
pubmed: 30622213
Biochim Biophys Acta. 2013 Jan;1833(1):122-39
pubmed: 23085373
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):128-137
pubmed: 29369779
Int J Mol Sci. 2021 Jun 14;22(12):
pubmed: 34198477
Genes (Basel). 2019 Dec 02;10(12):
pubmed: 31810288
Oncogene. 2019 Aug;38(31):5987-6001
pubmed: 31270394
Mol Cell. 1999 Dec;4(6):1029-40
pubmed: 10635327
Front Endocrinol (Lausanne). 2022 Jul 28;13:971162
pubmed: 35966060
FEBS Lett. 2011 Jun 23;585(12):1741-7
pubmed: 21570973
Mol Cell. 2007 Dec 14;28(5):730-8
pubmed: 18082598
Nat Commun. 2023 Jan 13;14(1):201
pubmed: 36639369
Int J Cancer. 2012 Sep 1;131(5):E614-24
pubmed: 22161689
Bio Protoc. 2023 Sep 20;13(18):e4816
pubmed: 37753472
Blood. 2006 Mar 15;107(6):2330-8
pubmed: 16322467
FEBS Lett. 2012 Aug 14;586(17):2773-7
pubmed: 22664379
Protein Sci. 2018 May;27(5):923-932
pubmed: 29498112

Auteurs

Pierluigi Scalia (P)

Istituto Somatogene per la Oncologia Personalizzata e la Ricerca Onco-Genomica (ISOPROG)-Somatolink Expert-Patients For Patients (EPFP) Research Network, Philadelphia, PA, United States.
Istituto Somatogene per la Oncologia Personalizzata e la Ricerca Onco-Genomica (ISOPROG)-Somatolink Expert-Patients For Patients (EPFP) Research Network, Caltanissetta, Italy.
Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, United States.

Stephen J Williams (SJ)

Istituto Somatogene per la Oncologia Personalizzata e la Ricerca Onco-Genomica (ISOPROG)-Somatolink Expert-Patients For Patients (EPFP) Research Network, Philadelphia, PA, United States.
Istituto Somatogene per la Oncologia Personalizzata e la Ricerca Onco-Genomica (ISOPROG)-Somatolink Expert-Patients For Patients (EPFP) Research Network, Caltanissetta, Italy.
Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, United States.

Classifications MeSH